Randomized, double-blind, placebo-controlled, crossover study of the effects of lisdexamfetamine dimesylate and mixed amphetamine salts on cognition throughout the day in adults with attention-deficit/hyperactivity disorder
Patrick T Martin, Mary Corcoran, Pinggao Zhang, Alain Katic, Patrick T Martin, Mary Corcoran, Pinggao Zhang, Alain Katic
Abstract
Background: Understanding the nature and time course of the pharmacodynamic effects of attention-deficit/hyperactivity disorder (ADHD) medications is useful. The Cognitive Drug Research Computerized Battery of Tests (CDR-CBT) is a 20-min battery of ten standardized, validated neuropsychometric tasks.
Objective: This pilot study examined the sensitivity and responsiveness of the CDR-CBT for assessing cognitive function in adults with ADHD prior to and up to 16 h postdose during treatment with lisdexamfetamine dimesylate (LDX) or mixed amphetamine salts immediate release (MAS-IR; various generics available).
Methods: This was a double-blind three-period crossover study. Participants received LDX 50 mg/day, MAS-IR 20 mg/day, and placebo (~7 a.m.) for 7 days each in randomized order. CDR-CBT was administered on day 1 of period 1 and day 7 of each period at scheduled times between -0.5 (predose) and 16 h postdose. Composite power of attention (PoA) score (sum of simple reaction time, choice reaction time, and digit vigilance speed) was the primary outcome measure. The Conners' Adult ADHD Rating Scales-Self-Report: Short Version (CAARS-S:S) was administered at baseline and on day 1 of period 1, and days 6 and 7 of each treatment period. Tertiary outcomes included CDR-CBT composite continuity of attention scores, its component task scores, cognitive reaction time, and response variability scores. No inferential statistical comparisons were conducted. Safety assessments included adverse events (AEs) and vital signs.
Results: This analysis included 18 participants (mean age 30.8 years); one withdrew because of AEs. Mean pretreatment PoA scores were 1175.9-1361.2 ms, scores commensurate with a normative age of >40 years. Maximum reductions in PoA scores with LDX and MAS-IR occurred at 5 h postdose at day 7 (least squares mean difference [95% CI] of -150.0 [-235.41 to -64.50] and -79.8 [-165.72 to 6.21] ms vs. placebo, respectively). CAARS-S:S scores were unchanged with LDX and MAS-IR (vs. placebo) at all postdose timepoints. Tertiary attention-related CDR-CBT outcomes were sensitive to LDX and MAS-IR (vs. placebo). Treatment-emergent AEs and vital signs were consistent with previous studies in adult ADHD.
Conclusion: In adults with ADHD, PoA scores indicated impaired attention at baseline and response to treatment with LDX and MAS-IR (vs. placebo), demonstrating value for measuring the time course of pharmacologic treatment effects.
Figures
References
- Barkley RA. Differential diagnosis of adults with ADHD: the role of executive function and self-regulation. J Clin Psychiatry. 2010;71(7):e17. doi: 10.4088/JCP.9066tx1c.
- Willcutt EG, Doyle AE, Nigg JT, et al. Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review. Biol Psychiatry. 2005;57(11):1336–1346. doi: 10.1016/j.biopsych.2005.02.006.
- Sandra Kooij JJ, Marije Boonstra A, Swinkels SH, et al. Reliability, validity, and utility of instruments for self-report and informant report concerning symptoms of ADHD in adult patients. J Atten Disord. 2008;11 (4):445–58.
- Cubillo A, Halari R, Ecker C, et al. Reduced activation and inter-regional functional connectivity of fronto-striatal networks in adults with childhood Attention-Deficit Hyperactivity Disorder (ADHD) and persisting symptoms during tasks of motor inhibition and cognitive switching. J Psychiatr Res. 2010;44(10):629–639. doi: 10.1016/j.jpsychires.2009.11.016.
- Biederman J, Fried R, Petty CR, et al. Cognitive development in adults with attention-deficit/hyperactivity disorder: a controlled study in medication-naive adults across the adult life cycle. J Clin Psychiatry. 2011;72(1):11–16. doi: 10.4088/JCP.09m05420pur.
- Rubia K, Halari R, Cubillo A, et al. Methylphenidate normalises activation and functional connectivity deficits in attention and motivation networks in medication-naive children with ADHD during a rewarded continuous performance task. Neuropharmacology. 2009;57(7–8):640–652. doi: 10.1016/j.neuropharm.2009.08.013.
- Biederman J, Seidman LJ, Petty CR, et al. Effects of stimulant medication on neuropsychological functioning in young adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(7):1150–1156. doi: 10.4088/JCP.v69n0715.
- Lis S, Baer N, Stein-en-Nosse C, et al. Objective measurement of motor activity during cognitive performance in adults with attention-deficit/hyperactivity disorder. Acta Psychiatr Scand. 2010;122(4):285–294. doi: 10.1111/j.1600-0447.2010.01549.x.
- Muniz R, Brams M, Mao A, et al. Efficacy and safety of extended-release dexmethylphenidate compared with d, l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study. J Child Adolesc Psychopharmacol. 2008;18(3):248–256. doi: 10.1089/cap.2007.0015.
- Wigal T, Brams M, Gasior M, et al. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behav Brain Funct. 2010;6:34. doi: 10.1186/1744-9081-6-34.
- Silva R, Muniz R, Pestreich LK, et al. Efficacy of two long-acting methylphenidate formulations in children with attention- deficit/hyperactivity disorder in a laboratory classroom setting. J Child Adolesc Psychopharmacol. 2005;15(4):637–654. doi: 10.1089/cap.2005.15.637.
- Brown TE, Brams M, Gao J, et al. Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults. Postgrad Med. 2010;122(5):7–17. doi: 10.3810/pgm.2010.09.2196.
- Gualtieri CT, Johnson LG. A computerized test battery sensitive to mild and severe brain injury. Medscape J Med. 2008;10(4):90.
- Wesnes KA. Cognitive function testing: the case for standardization and automation. J Br Menopause Soc. 2006;12(4):158–163. doi: 10.1258/136218006779160544.
- Simpson PM. The cognitive drug research computerized assessment system for demented patients: a validation study. Int J Geriatr Psychiatry. 1991;6:95–102. doi: 10.1002/gps.930060208.
- Keith MS, Stanislav SW, Wesnes KA. Validity of a cognitive computerized assessment system in brain-injured patients. Brain Inj. 1998;12(12):1037–1043. doi: 10.1080/026990598121945.
- Edgar C, Jongen PJ, Sanders E, et al. Cognitive performance in relapsing remitting multiple sclerosis: a longitudinal study in daily practice using a brief computerized cognitive battery. BMC Neurol. 2011;11:68. doi: 10.1186/1471-2377-11-68.
- Wesnes KA, Ward T, McGinty A, et al. The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology. 2000;152(4):353–361. doi: 10.1007/s002130000533.
- Kennedy DO, Scholey AB, Wesnes KA. The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers. Psychopharmacology. 2000;151(4):416–423. doi: 10.1007/s002130000501.
- Simpson D, Plosker GL. Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder. CNS Drugs. 2004;18:397–401. doi: 10.2165/00023210-200418060-00011.
- Wesnes K, Pincock C. Practice effects on cognitive tasks: a major problem? Lancet Neurol. 2002;1(8):473. doi: 10.1016/S1474-4422(02)00236-3.
- Vyvanse (lisdexamfetamine dimesylate) [package insert]. Wayne: Shire US Inc.; 2013.
- Adderall XR (mixed salts of a single-entity amphetamine product) [package insert]. Wayne: Shire US Inc.; 2011.
- Adler L, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004;27:187–201. doi: 10.1016/j.psc.2003.12.003.
- Barkley RA. Barkley adult ADHD rating scale–IV (BAARS-IV) New York: Guilford Press; 2011.
- Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20): 22–33;quiz 34–57.
- Conners CK, Erhardt D, Sparrow E. Conners’ adult ADHD rating scales (CAARS) technical manual. New York: Multi-Health Systems; 1999.
- Bush G. Attention-deficit/hyperactivity disorder and attention networks. Neuropsychopharmacology. 2010;35(1):278–300. doi: 10.1038/npp.2009.120.
- Hervey AS, Epstein JN, Curry JF. Neuropsychology of adults with attention-deficit/hyperactivity disorder: a meta-analytic review. Neuropsychology. 2004;18(3):485–503. doi: 10.1037/0894-4105.18.3.485.
- Tucha O, Mecklinger L, Laufkotter R, et al. Methylphenidate-induced improvements of various measures of attention in adults with attention deficit hyperactivity disorder. J Neural Transm. 2006;113(10):1575–1592. doi: 10.1007/s00702-005-0437-7.
- Cubillo A, Halari R, Smith A, et al. A review of fronto-striatal and fronto-cortical brain abnormalities in children and adults with Attention Deficit Hyperactivity Disorder (ADHD) and new evidence for dysfunction in adults with ADHD during motivation and attention. Cortex. 2012;48(2):194–215. doi: 10.1016/j.cortex.2011.04.007.
- Bush G. Cingulate, frontal, and parietal cortical dysfunction in attention-deficit/hyperactivity disorder. Biol Psychiatry. 2011;69(12):1160–1167. doi: 10.1016/j.biopsych.2011.01.022.
- Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. 2006;11:625–639.
- Jain U, Hechtman L, Weiss M, et al. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study. J Clin Psychiatry. 2007;68:268–277. doi: 10.4088/JCP.v68n0213.
- Adler LA, Goodman DW, Kollins SH, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(9):1364–1373. doi: 10.4088/JCP.v69n0903.
Source: PubMed